thehindu.com

Aurobindo Pharma Q1 net profit rises 25% and board approves unit merger

Aurobindo Pharma logoAurobindo Pharma
Sig2.65Sen+5.33Env0.00Soc0.00Gov+0.55

Aurobindo Pharma reported a 25.2% year-on-year rise in consolidated net profit to ₹1,032 crore in the June quarter, driven by higher revenue. The board approved merging wholly owned step-down subsidiaries Eugia Steriles and Eugia SEZ into Eugia Pharma Specialities to simplify group structure and cut corporate overheads. Revenue and API and formulations grew across regions, including strong U.S. and Europe performance.

Coverage (2)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro